troglitazone has been researched along with Coronary Restenosis in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Coronary Restenosis: Recurrent narrowing or constriction of a coronary artery following surgical procedures performed to alleviate a prior obstruction.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takagi, T | 1 |
| Yamamuro, A | 1 |
| Tamita, K | 1 |
| Yamabe, K | 1 |
| Katayama, M | 1 |
| Morioka, S | 1 |
| Akasaka, T | 1 |
| Yoshida, K | 1 |
1 trial available for troglitazone and Coronary Restenosis
| Article | Year |
|---|---|
Impact of troglitazone on coronary stent implantation using small stents in patients with type 2 diabetes mellitus.
Topics: Aged; Angioplasty, Balloon, Coronary; Chromans; Coronary Angiography; Coronary Artery Disease; Coron | 2002 |